Singapore, March 22, 2024 — Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.61 billion in 2023 with more than 5,600 employees.
Evonik Cell Culture Solutions
As part of Evonik Nutrition & Care, Cell Culture Solutions portfolio combines extensive development expertise and manufacturing capabilities to provide highly defined and pure cell culture ingredients for use in a wide range of applications, from biopharmaceutical R&D and manufacturing to medicinal purposes. Cell Culture Solutions offered by Evonik are a cornerstone to its expanding portfolio of biosolutions. Customers benefit from a tailored offering of ingredients, as well as application and formulation expertise as a system solution. Nutrition & Care aims to increase its share of system solutions to 70 percent by 2032.
Evonik’s solutions include the cQrex® portfolio of peptides that address specific amino acid limitations to improve stability and solubility, enabling optimal productivity and enhancing performance in biopharmaceutical cell culture media used for production of therapeutic proteins (mAbs, fusion proteins etc.) using varieties of CHO cells, Viral vector based gene therapy products using HEK 293 cells and stem cells (like MSCs) based cell therapies
Alongside cQrex®, Evonik cell culture solutions also offers other specialty ingredients like carbohydrates (monosaccharides): D-Galactose, D-Mannose added to cell culture media for partial to full replacement of traditional sugars like glucose/sucrose, to get rid of over production of lactate in culture process & better quality of therapeutic proteins with tuned glycosylation profiles. Veg derived cholesterol: PhytoChol® Biopharma which offers higher cell membrane stability for cholesterol auxotroph cell lines (NS0, insect cells etc.) during the culture process. High pure, low endotoxin levels based single amino acids as base ingredients for biopharma cell culture.
Winner of Best New Bioprocessing Supplier Award: Upstream Processing at ABEA Awards 2024
“It is a great honor to be recognized by the Asia-Pacific biopharma community for the second year in a row. We look forward to many more fruitful collaborations with companies in the region and look forward to exceeding their cell culture media and bioprocessing needs,” said Shirley Qi, President Southeast Asia, Australia & New Zealand/head of Nutrition & Care Asia Pacific at Evonik.
This award win played a considerable role in effective promotion of Evonik’s new peptide (launched in 2023): cQrex® KC (N,N-di-L-Lysyl-L-Cystine dihydrochloride) which is 1000 times more soluble than single amino acid L-Cystine, in neutral pH cell culture media in Asia Pacific countries. There are many specialty new ingredients in pipeline, planned for launch in 2024-25, targeted towards end applications in therapeutic proteins (mAbs, fusion proteins etc.), cell & gene therapy. Stay tuned to know more in this regards, in coming months.
“Winning this award is a testament to the efforts of our team to serve the biopharma community. Our success further encourages us to develop more innovative solutions to solve bioprocessing challenges with our cell culture solutions portfolio,” said Spandan Mishra, Associate Director Business Development – Biopharma Solutions at Evonik Health Care for Asia Pacific.
The ABEA 2024 was held in conjunction with 11th Biologics Manufacturing Asia, 8th BioLogistics World Asia and 2nd Clinical Trials Festival Asia on 20th March 2024 in Singapore, gathering hundreds of biopharma industry leaders. To learn more about ABEA 2024 awards, please visit.
About IMAPAC
IMAPAC is a leading event management company specializing in the biopharmaceutical industry. With over 12 years of experience, IMAPAC has successfully organized more than 50 industry events, attracting over 15,000 participants from around the world. IMAPAC’s events are renowned for their high-quality content, prestigious speakers, and networking opportunities.
